Abstract | Clinical evidence strongly suggests that certain live vaccines, in particular bacille Calmette-Guérin (BCG) and measles vaccines, can reduce all-cause mortality, most probably through protection against non-targeted pathogens in addition to the targeted pathogen. The underlying mechanisms are currently unknown. We discuss how heterologous lymphocyte activation and innate immune memory could promote protection beyond the intended target pathogen and consider how vaccinologists could leverage heterologous immunity to improve outcomes in vulnerable populations, in particular the very young and the elderly. that occurs as a consequence of this disease; as such, the vaccine also reduces non-measles mortality 4 . Moreover, there is increasing evidence that some vaccines can broadly enhance immune responses to a range of distinct pathogens or other vaccines (BOXES 2, 3) , which indicates that immune protection may be influenced by previous exposure to unrelated microorganisms or microbial components. The strongest evidence of such effects in humans relates to the apparent ability of the bacille Calmette-Guérin (BCG) vaccine (that is, a live attenuated Mycobacterium bovis) to reduce all-cause infant mortality in high-mortality settings [5] [6] [7] (TABLE 1). Similar benefits have been reported for other live attenuated vaccines, specifically the measles vaccine and the oral polio vaccine 8, 9 . The observed reductions in all-cause mortality seem to extend beyond the direct protection induced by these vaccines against their target pathogens and are likely to reflect the induction of resistance to unrelated pathogens through enhancement of heterologous adaptive immune responses and/or antigennonspecific innate immune mechanisms. These positive heterologous effects of certain live attenuated vaccines may not be limited to resource-poor settings. Indeed, certain live attenuated vaccines, such as measles, smallpox and polio vaccines, may also reduce infection-related hospitalization in developed countries by providing protection against unrelated pathogens [10] [11] [12] [13] . Heterologous effects do not just influence immune responses to pathogens; they have also been harnessed in the treatment of non-invasive bladder cancer,
The goal of vaccination is to induce an immune response against one or more antigens that results in persistent antibody production (to maintain levels of circulating and mucosal antibodies) and/or more efficient (that is, faster and/or increased) mobilization of adaptive immune cells (specifically, T cells and B cells) when an individual subsequently encounters a pathogen containing those antigens months or years later. Antigens can be delivered as purified molecules (for example, in subunit vaccines) or in a more complex format (for example, as components of live attenuated or inactivated microorganisms). Purified antigens are generally poorly immunogenic, and therefore adjuvants are used to boost their immunogenicity. Whole microorganisms often have intrinsic adjuvant activity owing in part to their immunostimulatory molecules, such as cell wall components and nucleotides that engage pattern recognition receptors (PRRs). However, even vaccines that deliver intact microorganisms may be enhanced by an additional adjuvant, especially in the case of inactivated vaccines. Aluminium salts (alum) are the most commonly used adjuvants in human vaccines, but microorganism-derived components and their synthetic congeners, and/or oil-in-water emulsions that engage and mortality that are not attributable to prevention of the disease (or diseases) targeted by the vaccine. We also use the term 'heterologous' to describe the activation of lymphocyte responses (antigen-specific or nonspecific) that are directed against non-target antigens.
In this Opinion article, we discuss how complex effects of antigens and adjuvants underlie immune responses to vaccines, with parallels to the development of immunity following natural infection. Moreover, we consider how these effects could account for the heterologous clinical effects of vaccination and reflect on the implications of vaccine-induced heterologous immunity for the optimization of immunization programmes.
Heterologous effects of vaccination
A major goal of modern vaccinology is to influence the magnitude, quality and durability of T cell and B cell responses using adjuvants, viral vectors, virus-like particles and other formulations and delivery vehicles to enhance immune responses 2 . The aim is to generate protective immunity in immunologically naive or less immunocompetent populations (especially the very young, who are the target of most vaccines, and the elderly) by boosting responses against 'weak' antigens and inducing responses that are more broadly protective against a range of microbial strains (for example, against several strains of influenza virus).
In addition to providing immune protection against their intended targets, vaccines may have other beneficial effects, such as broadening the diversity of cross-clade protection within an individual species. For example, the MF59-adjuvanted influenza vaccine provided expanded coverage to include related but antigenically distinct influenza virus strains in addition to the target strain 3 . Vaccines may also provide broader benefit by preventing opportunistic secondary infections. Indeed, a recent population-level analysis describing the post-disease immunosuppressive effects of measles infections argued that measles vaccination not only provides protection against the measles virus itself but also prevents the prolonged immunosuppression PRR pathways are increasingly attractive alternative adjuvants in the development of new vaccines 1, 2 . Vaccines have classically been thought to generate specificity and memory by the activation of antigen-induced adaptive immune responses that are mediated by T cells and B cells. Adjuvants may promote these responses by stimulating antigen acquisition and immunogenic presentation by antigen-presenting cells of the innate immune system, principally dendritic cells (DCs). However, as discussed below, accumulating evidence from clinical and laboratory studies indicates that heterologous activation of lymphocytes and innate immune memory mechanisms also shape the host response to vaccination.
Moreover, several lines of evidence suggest that certain vaccines influence immune responses either against other vaccines or against pathogens that are not targeted by the vaccine. These effects have variously been called 'heterologous' , 'nonspecific' or 'off-target' effects. As defined in BOX 1,  we herein use the term 'heterologous' to describe a vaccine that is designed to target a specific pathogen but also affects the host response to unrelated pathogens (or potentially to the host itself), with unanticipated effects on morbidity that occurs as a consequence of this disease; as such, the vaccine also reduces non-measles mortality 4 . Moreover, there is increasing evidence that some vaccines can broadly enhance immune responses to a range of distinct pathogens or other vaccines (BOXES 2,3), which indicates that immune protection may be influenced by previous exposure to unrelated microorganisms or microbial components. The strongest evidence of such effects in humans relates to the apparent ability of the bacille Calmette-Guérin (BCG) vaccine (that is, a live attenuated Mycobacterium bovis) to reduce all-cause infant mortality in high-mortality settings [5] [6] [7] (TABLE 1). Similar benefits have been reported for other live attenuated vaccines, specifically the measles vaccine and the oral polio vaccine 8, 9 . The observed reductions in all-cause mortality seem to extend beyond the direct protection induced by these vaccines against their target pathogens and are likely to reflect the induction of resistance to unrelated pathogens through enhancement of heterologous adaptive immune responses and/or antigennonspecific innate immune mechanisms. These positive heterologous effects of certain live attenuated vaccines may not be limited to resource-poor settings. Indeed, certain live attenuated vaccines, such as measles, smallpox and polio vaccines, may also reduce infection-related hospitalization in developed countries by providing protection against unrelated pathogens [10] [11] [12] [13] . Heterologous effects do not just influence immune responses to pathogens; they have also been harnessed in the treatment of non-invasive bladder cancer,
The above examples of heterologous effects indicate that the immunological consequences of infectious diseases, and the vaccines that prevent them, may influence immediate and future interactions of the host with antigens from unrelated organisms or from the host itself. These observations provide both opportunities and challenges in the design of vaccines and vaccination programmes, and call for a deeper, evidence-based understanding of the mechanisms underlying immune responses to both infection and vaccination. Although it is apparent that the nature of the antigen and adjuvant can have profound effects on the immune response to that antigen, it is less clear how they can also influence subsequent immune responses to other antigens, resulting in heterologous effects.
Heterologous lymphocyte responses
Antigen cross-reactivity resulting from molecular mimicry may be responsible for some heterologous effects (FIG. 1) . For example, adult humans (but not neonates) have been shown to possess memory T cells that are reactive to viral antigens to which they had not been exposed (including HIV, herpes simplex virus and cytomegalovirus (CMV)) and cross-reactive to antigenic peptides from non-targeted microorganisms 20 . The development of narcolepsy in some patients who received the AS03-adjuvanted H1N1 influenza pandemic vaccine may also be due to cross reactivity, in this case to host antigens 21 . Specifically, molecular mimicry between a fragment of in which local instillation of BCG is used to induce antitumour responses 14 . Negative heterologous effects have also been reported, including an association between the AS03-adjuvanted influenza pandemic vaccine that was widely used in Europe during the 2009 H1N1 influenza pandemic [15] [16] [17] and the development of narcolepsy in some children and infants 18, 19 . It has also been suggested that inactivated vaccines -such as the DTP (diphtheria, tetanus, pertussis) vaccine -may either have negative heterologous effects or oppose the positive heterologous effects of live vaccines 5 , although evidence for this is currently limited 7 .
Box 2 | Heterologous effects of vaccination
The strongest evidence for the heterologous effects of vaccination relates to the apparent ability of certain live attenuated vaccines to enhance immunity in an antigen-nonspecific manner, resulting in reduced all-cause mortality that probably reflects the induction of resistance to unrelated pathogens 5, 89 . Specifically, the World Health Organization (WHO) Strategic Advisory Group of Experts on immunization recently concluded that, based on available evidence, immunization with bacille Calmette-Guérin (BCG), which is a live attenuated Mycobacterium bovis strain vaccine, and with a live attenuated measles vaccine, has a possible beneficial effect on all-cause mortality in high-risk populations during the first weeks of life 5 (TABLE 1) . Oral polio vaccine has also been reported to reduce all-cause mortality in high-mortality settings 9 . Such benefits of live attenuated vaccines may not be limited to resource-poor settings. A retrospective analysis of epidemiological data from Spain suggested that BCG given at birth may decrease hospitalization owing to sepsis and respiratory infection 10 . Furthermore, cohort studies from Denmark have suggested that measles, smallpox and oral polio vaccines reduce the rate of infection-related hospitalization [11] [12] [13] . Research is ongoing to determine whether other types of vaccines, including inactivated vaccines, also exhibit heterologous effects, and to evaluate the potential for negative as well as positive effects 5 . Vaccines can also have heterologous effects (positive or negative) on host tissues. For example, the antitumour effects of BCG have been leveraged to treat non-invasive bladder cancer 14 .
Other vaccines have been implicated in the development of autoimmunity, such as the increased incidence of narcolepsy among children who received the AS03-adjuvanted H1N1 influenza vaccine 18, 21 .
Box 1 | Definitions: heterologous effects and mechanisms
A vaccine that confers protection against unrelated pathogens, in addition to the target pathogen, is described as having heterologous effects (BOX 2; TABLE 1). Heterologous effects of vaccination may persist for long periods
. Deleterious (negative) heterologous effects are also possible if vaccination impairs the ability of the host to combat infection with non-targeted pathogens. Vaccines may also have heterologous effects (positive or negative) that are directed against host tissues, such as induction of an antitumour response or autoimmune disease.
In some cases, heterologous effects can be attributed to antigen cross-reactivity, whereby lymphocytes that are specific for the vaccine antigen also recognize other antigens owing to molecular mimicry. However, most heterologous effects of vaccination cannot be explained by molecular mimicry.
Heterologous effects of vaccination may alternatively be mediated by heterologous immune responses that are not specifically directed against the vaccine antigen (FIGS 1,2). Heterologous lymphocyte responses include the broad effects of cytokines produced by activated T cells (for example, macrophage activation by interferon-γ) and activation of 'bystander' lymphocytes that are specific for non-targeted antigens. Heterologous immune responses can also involve lymphocyte-independent activation of innate immune cells. These effects may persist as a result of 'innate memory' mechanisms involving macrophages or natural killer cells. For example, 'trained immunity' arises from epigenetic reprogramming owing to sustained changes in gene expression and cell physiology, without permanent genetic changes such as mutations or recombination.
one of the influenza antigens (nucleoprotein) and a portion of the human brain receptor that promotes wakefulness (hypocretin receptor 2 (also known as OX2R)) provides a plausible explanation for this heterologous effect, although other mechanisms have been suggested 22 . Interestingly, during the same H1N1 influenza pandemic, a spike in childhood narcolepsy cases was also observed in China, where vaccination rates were very low 23 . It is possible that the same antigen cross-reactivity mechanism (that is, between the nucleoprotein of the infectious virus and the host hypocretin receptor 2) was responsible for the increased narcolepsy in this population, but this has not yet been demonstrated. Antigen cross-reactivity cannot, however, explain all the diverse heterologous effects that have been observed with other vaccines.
Heterologous lymphocyte activation may account for some of the heterologous effects of these vaccines. 'Bystander' activation of unrelated T cells and/or B cells following infectious or vaccine-induced immune stimulation may also help to sustain pre-existing antigen-specific immunity (FIG. 1) In any case, this is not likely to be the main mechanism for the beneficial heterologous effects of the BCG or measles vaccine in infants because of their frequent lack of pre-existing immunity to most pathogens and more limited durability of antibody responses than at older ages, which may be attributable in part to suboptimal support from the bone marrow 32, 33 . Cytokine production has also been suggested to underlie the heterologous effects of BCG (FIG. 1b) . Experiments conducted half a century ago demonstrated infection-induced 'cross-protection' between unrelated bacterial pathogens, and these pioneering observations played a crucial part in defining the concept of cell-mediated immunity 34 . This classical form of crossprotection is mediated by lymphocytes that produce interferon-γ (IFNγ) after stimulation by the first pathogen encountered (for example, BCG), thereby activating macrophages. This generates a state of heightened innate immunity against a secondary infection, which wanes rapidly once the initial pathogen is eliminated 35 . Some -but not all -studies in humans have reported that peripheral blood mononuclear cells that are harvested at various time points after BCG immunization exhibit increased production of IFNγ and other pro-inflammatory cytokines upon in vitro stimulation with mitogens or unrelated antigens 36 . Enhanced in vitro production of IFNγ following measles vaccination has also been reported in some studies 36 . By contrast, several studies have consistently shown reduced mitogen-induced proliferative responses following vaccination 36 . These apparently divergent results may reflect variation in randomization, controls, antigenic stimuli of the tetanus-specific antibody but also stimulates increased levels of antibodies that recognize measles and Toxoplasma gondii, either through enriched T cell help or other polyclonal stimuli 25, 26 . However, other studies failed to see a substantial impact of heterologous immunization on pre-existing antibody titres in humans 27 or on memory B cell responses in mouse models 28 . Thus, although polyclonal stimulation of B cell responses could contribute to sustained antibody responses throughout life, the evidence for this is inconsistent. When given at or around the same time as other vaccines, BCG may enhance the antibody response to those vaccines, acting as an adjuvant, although the specific effects and/or outcomes are a matter of debate [29] [30] [31] .
Box 3 | Durability of heterologous effects of vaccination
Data describing the durability of heterologous protection following vaccination are limited. In the randomized controlled trials that provide some of the strongest evidence of a beneficial effect, the bacille Calmette-Guérin (BCG) vaccine given at birth in a high-risk population in Guinea-Bissau was associated with a reduction in all-cause mortality of 58%, 48% and 21% over the first few days, first month and first year of life, respectively 90 . This might suggest that protection waned rapidly. However, it is possible that the apparent reduction in all-cause mortality over time was related to a gain in protection among individuals in the control group who subsequently received the vaccine (from 6 weeks of age onwards).
Similarly, a study of all-cause mortality following measles vaccination in infants also suggested that protection is greatest in the first weeks to months after vaccination 8 , but the apparent diminution in heterologous protection may also be due in part to confounding factors.
At least one study suggests that heterologous effects can persist for more than a decade. An epidemiological study of 10-14-year-old children in Spain reported 69.6% fewer incidents of hospitalization owing to respiratory infections that were not attributable to tuberculosis among those who had received the BCG vaccine at birth, compared with those who had not received the BCG vaccine 10 . Mechanistic studies are consistent with the possibility that at least some heterologous effects may be durable. Heterologous lymphocyte responses may persist for decades in memory cells, and innate immune memory may be maintained by epigenetic reprogramming of long-lived differentiated cells (including tissue-resident macrophages) or haematopoietic progenitors. Indeed, some heterologous responses to non-mycobacterial stimuli have been reported to remain strongly elevated 1 year after BCG vaccination of healthy adults 91 . and the in vitro assays used. It is therefore difficult to draw robust conclusions regarding the impact of live attenuated vaccines on cytokine induction from the available data. An enhanced pro-inflammatory cytokine milieu after measles and BCG vaccination might contribute to the increased protective immunity and reduced all-cause mortality that are observed with these vaccines. However, a clear pattern has not been determined for the antigenic requirements, timing, nature or persistence of these effects, nor their influence on subsequent antibody or T cell responses. Moreover, there is currently no direct evidence in humans that such immunological phenomena are the basis for the epidemiological observations of reduced mortality following the administration of live vaccines in high-mortality settings. Indeed, the immunological mechanisms underlying both the mycobacteria-targeting and the heterologous effects of BCG remain incompletely defined despite over 50 years of laboratory and animal studies highlighting its immunomodulatory properties [37] [38] [39] .
Innate immune memory
In addition to the impact of lymphocytederived cytokines such as IFNγ on innate immune cells, recent evidence suggests that innate immune cells, especially monocytes, macrophages and natural killer (NK) cells, possess intrinsic memory characteristics and may make a greater contribution to the heterologous protective effects of vaccines than T cell-and B cell-based adaptive immune mechanisms.
Of note, immunization with certain live microorganisms or microbial components that activate innate immune cells can protect mice against lethal infection with distinct pathogens. For example, heterologous immunity is induced by fungal β-glucans against infection with Staphylococcus aureus bacteria 40, 41 , by the peptidoglycan component muramyl dipeptide against T. gondii parasites 42 , by CpG oligodeoxynucleotide against Escherichia coli meningitis 43 and by flagellin against Streptococcus pneumoniae and rotavirus 44, 45 . The broad characteristics of this protection implicate innate immune mechanisms rather than classical antigen-specific adaptive immune memory.
Bacteria, fungi, parasites and viruses can exert long-term immunomodulatory effects that have been demonstrated -using T celland B cell-deficient or lymphocyte-depleted animals -to be independent of adaptive immunity. BCG vaccination of animals induces T cell-and B cell-independent protection against secondary infections with a T cell-and B cell-independent mechanism 50, 51 . Latent infection of mice with gamma-herpesvirus also increases T cellindependent resistance to unrelated bacterial pathogens, such as Listeria monocytogenes and Yersinia pestis 52 , owing to sustained IFNγ production and systemic macrophage activation. Similarly, the helminth parasite Nippostrongylus brasiliensis induces a long-term macrophage phenotype that damages the parasite and induces protection against reinfection independently of T cells and B cells 53 . 46, 47 , demonstrating that innate immune mechanisms mediate at least some of the heterologous protective effects of vaccination in these models. Moreover, the protection that is conferred by an attenuated strain of C. albicans (PCA-2) against disseminated candidiasis (owing to the CA-6 strain of C. albicans) is dependent on macrophages 48 and pro-inflammatory cytokines 49 . This protection can also be induced in athymic mice and recombination-activating gene 1 (RAG1)-deficient animals, demonstrating Nature Reviews | Immunology 'Trained immunity' , whereby the responses of innate immune cells such as monocytes and macrophages are primed by previous exposure to the same or an unrelated stimulus 54 (FIG. 2) , may underlie some of the heterologous effects of vaccination. For example, exposure of monocytes or macrophages to C. albicans or β-glucan enhances their subsequent response to stimulation with unrelated pathogens or pathogen-associated molecular patterns 51 . components. However, in contrast to its effects on inflammatory cytokine production, antimicrobial responses are primed by previous LPS exposure 55 . Although the functional programme may be different from that induced by β-glucan or other vaccine adjuvants, conceptually the long-term functional reprogramming of innate immune cells by LPS can be considered similar to trained immunity. Thus, innate memory is shaped by a combination of positive and negative effects at the molecular level (often simultaneously within the same cell) (FIG. 2b) that ultimately influence subsequent responses to related or unrelated pathogens.
Candida albicans or Schistosoma mansoni
Epigenetic reprogramming probably underlies these effects. LPS stimulation of macrophages induces gene-specific chromatin modifications that simultaneously silence genes coding for inflammatory molecules (that is, tolerance) and promote the expression of genes coding for antimicrobial molecules (that is, priming) 55 .
Monocyte training by C. albicans and β-glucan is also accompanied by distinct reprogramming of chromatin marks, and blockade of histone methylation has been shown to impair the induction of trained immunity 51, 56 . Metabolic shifts in the trained monocytes from oxidative phosphorylation to glycolysis (known as the 'Warburg effect') are also important for the induction of trained immunity 57 . Several metabolites may function as cofactors for epigenetic enzymes 58 , and investigation of the impact of changes in cellular metabolism on the epigenetic programme of innate immune cells is an important focus of ongoing research.
Autophagy has also been implicated in the development of trained immunity. A recent study showed that epigenetic reprogramming of monocytes by BCG in vitro is dependent on autophagy 59 . Blocking autophagy abrogated the in vitro training effect of BCG, and monocyte training in vitro and in vivo was also influenced by genetic variation in the autophagy related 2B (ATG2B) gene. Moreover, the same polymorphism correlates with responsiveness to intravesical BCG instillation in patients with non-invasive bladder cancer 59 . NK cells can also respond more vigorously after previous encounters with pathogens or other activation events. Indeed, the heterologous protective effects of BCG vaccination may be mediated in part by the activation of NK cells. NK cells from BCG-vaccinated individuals exhibit enhanced production of pro-inflammatory Innate immune memory can induce various functional programmes, some of which are characterized by a combination of suppressive and stimulatory effects. This is best exemplified by lipopolysaccharide (LPS)-induced 'tolerance' . LPS confers long-lasting innate immune effects on monocytes and macrophages, resulting in reduced inflammatory cytokine production upon either restimulation with LPS or subsequent exposure to unrelated microbial Nature Reviews | Immunology their progenitors to certain microbial stimuli induces epigenetic marks and metabolic changes that persist for extended periods and influence the sub sequent responses of these cells to the same or distinct stimuli. Priming or training increases the subsequent response, whereas tolerance reduces responsiveness. b | Priming or training and tolerance can occur simultaneously within the same cell, with the expression of some genes being promoted and others suppressed. c | The effects of innate memory may be long lived owing to the persistence of self-renewing macrophages in tissues or of exposed progenitors that continue to yield monocytes and macrophages with altered function for extended periods. Innate memory may be maintained indefinitely, or it may wane over time.
cytokines in response to mycobacteria and other unrelated pathogens; in mice, NK cells help to mediate the heterologous protective effects of BCG against C. albicans 60 . Moreover, several recent studies have reported that NK cells develop adaptive immune characteristics after infection with mouse CMV (MCMV) [61] [62] [63] 109 . NK cells bearing killer cell lectin-like receptor 8 (KLRA8; also known as LY49H) persist for months in lymphoid and non-lymphoid organs after MCMV infection; upon reinfection, these 'memory' NK cells undergo a secondary clonal expansion, rapidly degranulating and releasing cytokines, thereby inducing a protective immune response 53 . NK cell memory may also involve the IL-12-IFNγ axis 63 and activation of the co-stimulatory molecule DNAM1 (DNAX accessory molecule 1; also known as CD226) 64 . Evidence in support of NK cell memory is almost entirely derived from mouse studies 65 , but a recent report showed that simian immunodeficiency virus infection and viral vectored-vaccines induce NK cell memory in macaques that can persist for up to 5 years 66 . However, this immunity, similarly to NK cell memory induced by MCMV or hapten sensitization in mice [67] [68] [69] , was specific to the priming agent. Thus, unlike the heterologous effects that are seen in trained monocytes and macrophages, NK cell memory may provide pathogen specificity. MCMV-induced NK cell memory, for example, seems to be specific for MCMV and to impair NK cell responses to other pathogens such as influenza and L. monocytogenes 68 . Depending on the conditions, NK cells are therefore able to use both trained immunity, which may be mediated by epigenetic changes 62, 70 , and antigen-specific memory.
An important aspect to be considered regarding trained immunity is the lifespan of innate immune cells, particularly monocytes and the macrophages that are derived from them. In humans, trained monocytes can be observed in the circulation for at least 3 months after BCG vaccination 60 . This observation suggests that reprogramming also takes place at the level of progenitor cells to account for the persistence of modified populations of these relatively short-lived cells (FIG. 2c) . Indeed, the effects of microbial exposure on innate immune memory can be transferred from haematopoietic stem and progenitor cells to their progeny. For instance, haematopoietic stem and progenitor cells that are exposed to Toll-like receptor 2 (TLR2) agonists generate macrophages that all-cause morbidity and mortality, despite not meeting the main criteria for efficacy in this clinical study 79, 80 . A recent study reported that the early immune response of healthy adults to the monovalent AS03-adjuvanted H1N1 influenza vaccine changes significantly after the age of ~35 years 81 . The immune system undergoes development throughout childhood. T helper 1 (T H 1)-type cytokines (such as tumour necrosis factor (TNF), IL-12 and IFNγ), NK cell cytotoxicity, antigenspecific T H 1 cell responses and high-affinity antibody production are all low during the neonatal period and gradually increase over time [73] [74] [75] .
The impact of age
The heterologous effects of infection and vaccination are likely to be affected by age. Indeed, the beneficial heterologous effects of BCG were most evident when the vaccine was given early in life 7 . Moreover, narcolepsy following the monovalent AS03-adjuvanted H1N1 influenza pandemic vaccine was primarily observed in children and adolescents, and decreased as the subjects approached adulthood [76] [77] [78] . By contrast, in elderly subjects, a related vaccine enhanced protection against some influenza subtypes compared to the non-adjuvanted trivalent seasonal influenza vaccine and decreased Infants also have a lower capacity to mount robust and durable antibody responses. T cell-dependent antibody responses reach near-adult competence by 1 year of age, and T cell-independent responses by 2-4 years of age 94 . Infant natural killer (NK) cells are approximately half as effective as adult NK cells at killing most targets, although their cytotoxic capacity can be augmented by T H 1 cell-promoting cytokines and approaches that of adult cells by 1 year of age 92 . Limited neutrophil mobilization and mononuclear phagocyte function (including their responsiveness to interferon-γ) may also contribute to susceptibility to infection in neonates.
Postnatal immune development is profoundly influenced by the commensal microbiota, which is initially acquired from the mother during vaginal delivery and matures thereafter in an age-and environment-dependent manner [95] [96] [97] [98] , as well as pathogens and live vaccines. Human newborn and adult monocytes exhibit distinct responses to adjuvants and licensed adjuvanted vaccines in vitro that demonstrate age-and adjuvant-specific correlations to adjuvanted vaccine-induced responses in vivo 99 . Moreover, Toll-like receptor agonist administration to newborn mice enhances their subsequent cytokine and phagocytic responses to polymicrobial sepsis 100 , and early inflammatory or innate immune-activating events in humans are associated with reduced risk of late-onset sepsis 82, 83 . reduced vaccine efficacy 84, 85 . Thymic involution, restricted lymphocyte clonality and declining antimicrobial innate immune function contribute to suboptimal responses to many vaccine antigens and adjuvants. Little is known about the heterologous effects of vaccination in elderly populations or the impact of immunosenescence on heterologous lymphocyte responses and trained immunity. Dysregulated cytokine responses that are associated with immunosenescence following a lifetime of microbial exposure may lead to diminished trained immunity, but this remains to be investigated.
Perspectives for vaccinology
The studies and mechanisms described above present vaccinologists with exciting opportunities, as well as several challenges, in relation to the design of new vaccines and the development of vaccination programmes. Positive heterologous effects mediated by innate and/or adaptive immune mechanisms could be leveraged to confer broader protection against a range of pathogens. If a 'super-protective' state could be induced by vaccination, even if only for a brief window of exquisite infectious susceptibility, such as the neonatal period, important improvements in health could be realized. Conversely, the potential for negative heterologous effects must also be considered in order to improve vaccine efficacy and safety.
High-quality randomized controlled trials are needed to establish the heterologous effects (both pathogenspecific and nonspecific) of vaccines in diverse populations to define, for example, the impact of age, genetics, geographical location and sociological factors. These studies must be accompanied by thorough characterization of immunological correlates of clinically observed heterologous effects, including phenotypic and molecular changes in monocytes, NK cells, lymphocytes and other leukocytes. Model organisms should also be used to establish the role of proposed immune mechanisms in the observed effects. Bioinformatics tools will enable the refinement of vaccine antigens to exclude those that are potentially cross-reactive, thus limiting the negative effects. In addition, positive and negative heterologous effects could be predicted by taking advantage of new technologies such as human in vitro platforms that model age-specific immunity 1 and powerful systems biology approaches 81, 86, 87 that can now be used with small sample volumes 88 .
Defining mechanisms of heterologous lymphocyte activation and innate immune memory in early life and the elderly is of particular importance because infectioninduced mortality is highest in the first year of life, and ageing-associated susceptibility to infection is placing increasing pressure on health-care resources in the developed world. Given the burden of infection in those at the extremes of age, an effective plan is needed that engages funding agencies and other stakeholders to mobilize the resources required to leverage these newly discovered immunological pathways to reduce infection-induced morbidity and mortality.
